Cancer  /  Future Value

42 Matching Facts

Search matching Facts:
No results to display
    • FDA approved cancer advances
       
    • Thousands of potential cancer medicines in development
       
    • Estimated Number of Cancer Survivors in the United States From 1975 to 2012  
    • Over the next 10 years, the number of cancer survivors in the U.S. is predicted to grow from 14.5 million to nearly 19 million (9.3 million men and 9.6 million…  
    • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.  
    • As of July 2014, 18 anticancer drugs received FDA approval after being designated breakthrough therapies.  
    • Between August 2004 and July 2014, the FDA approved: Six new anticancer therapeutics Five new uses for previously approved anticancer therapeutics Two new uses for imaging agents One new use for a screening test  
    • A one percent reduction in cancer-related deaths in the U.S. would be worth an estimated $500 billion to society from increased quality of life and increased productivity from longer lives.  
    • A 10 percent reduction in cancer-related deaths in the U.S. would be worth an estimated $4.4 trillion to current and future generations.  
    • A one percent reduction in lung, colorectal, breast, leukemia, pancreatic, and brain cancer mortality would reduce productivity costs by $814 million per year.  
    • More than half of cancer deaths in the U.S. are due to preventable causes.  
    • Increased use of medical technology, like colonoscopy and sigmoidoscopy for colon cancer screening, could save $178.2 billion between 2010 and 2035.  
    • Pathogens cause around two million cancer cases worldwide each year. Ninety percent of these cases are attributable to Helicobacter pylori (H Pylori), hepatitis B virus (HBV), hepatitis C virus (HCV),…  
    • If the use of recommended colorectal screening increased to 70.5 percent, 1,000 additional lives could be saved each year.  
    • In 1971, one in 69 people was a cancer survivor (three million survivors). In 2014, that number grew to one in 22 people (14.5 million survivors).  
    • Medicines in Devlopment for Cancer, 2008  
    • 750 cancer-fighting medicines are currently in development.  
    • Following the current path, the colon cancer incidence rate will increase by 31.8% between 2003 and 2023 (447,000 people). If an alternative path is taken, there will be 17.7% (79,000…  
    • Following the current path, the lung cancer incidence rate will increase by 34% between 2003 and 2023. If an alternative path is taken, there will be 18.4% (92,000) fewer lung…  
    • Following the current path, the prostate cancer incidence rate will increase by 75.4% (786,000) between 2003 and 2023. If an alternative path is taken, there will be 21.5% (393,000) fewer…  
    • Medicines in Development for Cancer  
    • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development is for glioblastoma. The medicine singles out and latches onto the receptors on…  
    • According to the Pharmaceutical Research and Manufacturers of America, researchers are currently working on 646 medicines for cancer. All are either in clinical trials or under FDA review. …  
    • According to the Pharmaceutical Research and Manufacturers of America, a radiopharmaceutical currently in development is a synthetic version of a substance derived from scorpions–chlorotoxin. This could be a powerful…  
    • According to the Pharmaceutical Research and Manufacturers of America, a number of vaccines are being studied that would cause the body’s own immune system to fight cancer after it has…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine to fight breast cancer is currently in the pipeline. It targets the Bcl-2 protein, which appears to contribute…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.…  
    • According to the Pharmaceutical Research and Manufacturers of America, a medicine currently in development may delay the worsening of liver cancer. The medicine is an oral signal transduction inhibitor…  
    • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.  
    • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in development is designed to induce a powerful immune response to melanoma.  
    • For women age 40 or older, timely mammograms could reduce breast cancer mortality by about 16%–compared to those who are not screened.  
    • An experimental drug may help those women whose breast cancer worsens despite use of other therapies. The medicine was shown in studies to nearly double the time breast cancer…  
    • An experimental drug has been found to extend the lives of kidney patients by about 3.5 months–from 7 to just under 11. It has also been shown to delay…  
    • If the 1 million surgical breast biopsies performed annually were instead performed using image-guided needle core biopsy, the total savings could be $1.6 billion a year.  
    • Medical research that resulted in a 1/5 reduction in deaths from cancer would be worth $10 trillion to Americans-double the national debt.  
    • Widespread use of telomerase inhibitors could result in a 50% cure rate and a 25% prolongation of life for 50% of eligible patients with solid tumors.  
    • Widespread use of selective estrogen receptor modulators could result in an approximately 30% decrease in breast cancer.  
    • Widespread use of cancer vaccines could result in a cure of melanoma/renal cell carcinomas and a 25% boost in survival for all other cancers.  
    • A modest 1% reduction in cancer mortality would be worth close to $500 billion. A cure for cancer (if one is feasible) would be worth around $50 trillion.